KMT2A and acute myeloid leukemia: MLL-PTD AML patients with DNMT3A mutations had inferior EFS (median 0 vs. 6.8 months, P = 0.026) and OS (median 6.0 vs. 11.5 months, P = 0.032) compared to those without DNMT3A mutations (Figure 2C–2D).